造血-话题@MedSci

#造血#

356篇内容 | 2791人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1494674, encodeId=e4cb14946e4c8, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Lancet haemat：多发性骨髓瘤患者进行自体造血细胞移植前的预处理, objectType=article, longId=164440, objectId=fa3a164440b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa3a164440b4, replyNumber=0, likeNumber=82, createdTime=2019-04-18, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa3a164440b4, moduleTitle=Lancet haemat：多发性骨髓瘤患者进行自体造血细胞移植前的预处理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa3a164440b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494673, encodeId=2dd514946e36b, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, objectType=article, longId=164438, objectId=87fe1644385f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87fe1644385f, replyNumber=0, likeNumber=27, createdTime=2019-04-18, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87fe1644385f, moduleTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87fe1644385f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494672, encodeId=5fd414946e2a0, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：染色质结合蛋白Phf6可限制造血干细胞自我更新, objectType=article, longId=164290, objectId=28bf164290eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28bf164290eb, replyNumber=0, likeNumber=74, createdTime=2019-04-16, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28bf164290eb, moduleTitle=Blood：染色质结合蛋白Phf6可限制造血干细胞自我更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28bf164290eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494671, encodeId=4abb14946e13b, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：Asrij/OCIAD1可抑制CSN5介导的p53降解，维持造血干细胞静态, objectType=article, longId=164176, objectId=fcda1641e6a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcda1641e6a6, replyNumber=0, likeNumber=58, createdTime=2019-04-14, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcda1641e6a6, moduleTitle=Blood：Asrij/OCIAD1可抑制CSN5介导的p53降解，维持造血干细胞静态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcda1641e6a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494670, encodeId=266414946e014, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：循环血中的肿瘤DNA可用于预测AML/MDS患者造血干细胞移植后的复发风险, objectType=article, longId=163732, objectId=7ea3163e3222, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ea3163e3222, replyNumber=0, likeNumber=89, createdTime=2019-04-08, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ea3163e3222, moduleTitle=Blood：循环血中的肿瘤DNA可用于预测AML/MDS患者造血干细胞移植后的复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ea3163e3222)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494669, encodeId=31db1494669db, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=京津冀三省市医疗协作发展：他们这样“造血”, objectType=article, longId=163523, objectId=33001635238a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33001635238a, replyNumber=0, likeNumber=94, createdTime=2019-04-04, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33001635238a, moduleTitle=京津冀三省市医疗协作发展：他们这样“造血”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33001635238a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494668, encodeId=7d3714946684a, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：艾曲波帕（eltrombopag）可在IFNγ介导的炎性环境中维持人造血干/祖细胞的存活和功能, objectType=article, longId=163408, objectId=1a0e163408e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0e163408e3, replyNumber=0, likeNumber=75, createdTime=2019-04-03, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0e163408e3, moduleTitle=Blood：艾曲波帕（eltrombopag）可在IFNγ介导的炎性环境中维持人造血干/祖细胞的存活和功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0e163408e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494667, encodeId=7102149466efd, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=NCCN临床实践指南：造血生长因子（2019.V1）, objectType=article, longId=163338, objectId=f02d1633386b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f02d1633386b, replyNumber=0, likeNumber=25, createdTime=2019-04-01, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f02d1633386b, moduleTitle=NCCN临床实践指南：造血生长因子（2019.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f02d1633386b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494666, encodeId=4b69149466632, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=2019 EBMT共识建议：单倍体造血干细胞移植供者的选择, objectType=article, longId=162846, objectId=a92e16284603, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a92e16284603, replyNumber=0, likeNumber=55, createdTime=2019-03-25, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a92e16284603, moduleTitle=2019 EBMT共识建议：单倍体造血干细胞移植供者的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a92e16284603)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494665, encodeId=c1ac149466544, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：抗CD117抗体可同时清除正常的和异常的造血干细胞！, objectType=article, longId=162489, objectId=d00416248941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d00416248941, replyNumber=0, likeNumber=82, createdTime=2019-03-18, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d00416248941, moduleTitle=Blood：抗CD117抗体可同时清除正常的和异常的造血干细胞！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d00416248941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494664, encodeId=93ee149466493, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=ECIL-7指南：造血干细胞移植受者的疫苗接种, objectType=article, longId=160689, objectId=6db6160689a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6db6160689a0, replyNumber=0, likeNumber=53, createdTime=2019-02-22, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6db6160689a0, moduleTitle=ECIL-7指南：造血干细胞移植受者的疫苗接种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6db6160689a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494663, encodeId=70491494663eb, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=AGING CELL：表观年龄是移植人造血细胞的内在特性, objectType=article, longId=159721, objectId=db6b159e2179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db6b159e2179, replyNumber=0, likeNumber=61, createdTime=2019-02-12, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db6b159e2179, moduleTitle=AGING CELL：表观年龄是移植人造血细胞的内在特性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db6b159e2179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494662, encodeId=ff69149466225, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：内皮蛋白C受体（Epcr）可促进造血干细胞植入Mpl缺陷型小鼠并扩增, objectType=article, longId=159656, objectId=8fd115965637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fd115965637, replyNumber=0, likeNumber=72, createdTime=2019-02-10, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fd115965637, moduleTitle=Blood：内皮蛋白C受体（Epcr）可促进造血干细胞植入Mpl缺陷型小鼠并扩增, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fd115965637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494661, encodeId=e20514946610f, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：通过抑制PAPD5调节TERC的转录后修饰可恢复角化不良患者的终末造血, objectType=article, longId=159608, objectId=5638159608a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5638159608a6, replyNumber=0, likeNumber=77, createdTime=2019-02-09, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5638159608a6, moduleTitle=Blood：通过抑制PAPD5调节TERC的转录后修饰可恢复角化不良患者的终末造血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5638159608a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494660, encodeId=6a16149466062, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=造血干细胞移植治疗淋巴瘤中国专家共识（2018版）, objectType=article, longId=159443, objectId=887a15944304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=887a15944304, replyNumber=0, likeNumber=18, createdTime=2019-02-04, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=887a15944304, moduleTitle=造血干细胞移植治疗淋巴瘤中国专家共识（2018版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=887a15944304)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494659, encodeId=328e149465928, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=INT J LAB HEMATOL：利用CD81/CD58的表达率很容易从B细胞祖细胞急性淋巴细胞白血病患者淋巴母细胞中识别造血细胞, objectType=article, longId=159378, objectId=d85f1593e830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d85f1593e830, replyNumber=0, likeNumber=48, createdTime=2019-02-03, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d85f1593e830, moduleTitle=INT J LAB HEMATOL：利用CD81/CD58的表达率很容易从B细胞祖细胞急性淋巴细胞白血病患者淋巴母细胞中识别造血细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d85f1593e830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494658, encodeId=57cc1494658c9, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：内皮糖蛋白对维持造血干细胞静止至关重要, objectType=article, longId=158679, objectId=ad151586e929, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad151586e929, replyNumber=0, likeNumber=93, createdTime=2019-01-24, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad151586e929, moduleTitle=Blood：内皮糖蛋白对维持造血干细胞静止至关重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad151586e929)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494657, encodeId=8900149465e9a, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：HCT-CI评分可预测非恶性血液病患者进行造血细胞移植后的死亡风险, objectType=article, longId=157423, objectId=953415e4233d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=953415e4233d, replyNumber=0, likeNumber=79, createdTime=2019-01-07, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=953415e4233d, moduleTitle=Blood：HCT-CI评分可预测非恶性血液病患者进行造血细胞移植后的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=953415e4233d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494656, encodeId=eecf14946563d, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人, objectType=article, longId=155661, objectId=4497155661dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4497155661dc, replyNumber=0, likeNumber=70, createdTime=2018-12-14, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4497155661dc, moduleTitle=J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4497155661dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1494655, encodeId=8d3f1494655f2, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, objectTitle=Blood：Enasidenib治疗携带IDH2突变的AML患者可获得分子和造血缓解, objectType=article, longId=155214, objectId=b61e15521459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61e15521459, replyNumber=0, likeNumber=65, createdTime=2018-12-08, rootId=0, userName=俅侠, userId=caed9138962, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61e15521459, moduleTitle=Blood：Enasidenib治疗携带IDH2突变的AML患者可获得分子和造血缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61e15521459)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

造血

2020-05-29

俅侠 (审核中...)

前往app查看评论内容

#造血#

Lancet haemat：多发性骨髓瘤患者进行自体造血细胞移植前的预处理

2019-04-18

俅侠 (审核中...)

前往app查看评论内容

#造血#

Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估

2019-04-18

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：染色质结合蛋白Phf6可限制造血干细胞自我更新

2019-04-16

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：Asrij/OCIAD1可抑制CSN5介导的p53降解，维持造血干细胞静态

2019-04-14

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：循环血中的肿瘤DNA可用于预测AML/MDS患者造血干细胞移植后的复发风险

2019-04-08

俅侠 (审核中...)

前往app查看评论内容

#造血#

京津冀三省市医疗协作发展：他们这样“造血”

2019-04-04

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：艾曲波帕（eltrombopag）可在IFNγ介导的炎性环境中维持人造血干/祖细胞的存活和功能

2019-04-03

俅侠 (审核中...)

前往app查看评论内容

#造血#

NCCN临床实践指南：造血生长因子（2019.V1）

2019-04-01

俅侠 (审核中...)

前往app查看评论内容

#造血#

2019 EBMT共识建议：单倍体造血干细胞移植供者的选择

2019-03-25

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：抗CD117抗体可同时清除正常的和异常的造血干细胞！

2019-03-18

俅侠 (审核中...)

前往app查看评论内容

#造血#

ECIL-7指南：造血干细胞移植受者的疫苗接种

2019-02-22

俅侠 (审核中...)

前往app查看评论内容

#造血#

AGING CELL：表观年龄是移植人造血细胞的内在特性

2019-02-12

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：内皮蛋白C受体（Epcr）可促进造血干细胞植入Mpl缺陷型小鼠并扩增

2019-02-10

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：通过抑制PAPD5调节TERC的转录后修饰可恢复角化不良患者的终末造血

2019-02-09

俅侠 (审核中...)

前往app查看评论内容

#造血#

造血干细胞移植治疗淋巴瘤中国专家共识（2018版）

2019-02-04

俅侠 (审核中...)

前往app查看评论内容

#造血#

INT J LAB HEMATOL：利用CD81/CD58的表达率很容易从B细胞祖细胞急性淋巴细胞白血病患者淋巴母细胞中识别造血细胞

2019-02-03

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：内皮糖蛋白对维持造血干细胞静止至关重要

2019-01-24

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：HCT-CI评分可预测非恶性血液病患者进行造血细胞移植后的死亡风险

2019-01-07

俅侠 (审核中...)

前往app查看评论内容

#造血#

J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人

2018-12-14

俅侠 (审核中...)

前往app查看评论内容

#造血#

Blood：Enasidenib治疗携带IDH2突变的AML患者可获得分子和造血缓解

2018-12-08

科室
- - 订阅+
  - 更多科室
工具
服务